Neurovascular coupling (NVC) refers to the dynamic relationship between neural activity and cerebral blood flow (CBF), ensuring that brain regions receive adequate metabolic supply in response to neuronal demands. The neurovascular unit (NVU) — comprising neurons, astrocytes, pericytes, endothelial cells, and smooth muscle cells — coordinates this coupling through vasoactive signaling, myogenic responses, and metabolic feedback. NVC dysfunction is an early and progressive feature across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD), though the pattern and severity of impairment varies by disease and regional vulnerability.
Neurovascular coupling (NVC) refers to the dynamic relationship between neural activity and cerebral blood flow (CBF), ensuring that brain regions receive adequate metabolic supply in response to neuronal demands. The neurovascular unit (NVU) — comprising neurons, astrocytes, pericytes, endothelial cells, and smooth muscle cells — coordinates this coupling through vasoactive signaling, myogenic responses, and metabolic feedback. NVC dysfunction is an early and progressive feature across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD), though the pattern and severity of impairment varies by disease and regional vulnerability.
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|:------------------:|:------------------:|:---:|:---:|:--------------------:|
| NVU component affected | Pericytes, endothelium | Endothelium, astrocytes | Pericytes, endothelium | Endothelium, pericytes | Endothelium, vascular smooth muscle |
| Regional CBF reduction | Posterior cingulate, parietal | Substantia nigra, frontal | Motor cortex, spinal cord | Frontal, anterior temporal | Striatum, cortex |
| NVC impairment severity | Moderate-Severe (20-50%) | Moderate (15-35%) | Moderate (20-40%) | Moderate-Severe (25-45%) | Moderate (20-35%) |
| BBB breakdown timing | Early (preclinical) | Late (advanced stages) | Early (overlapping with neuroinflammation) | Early (especially GRN, C9orf72) | Early (striatal vessels) |
| Cerebral autoregulation | Impaired | Impaired | Variable | Impaired | Impaired |
| Amyloid angiopathy (CAA) | Present (50-70%) | Absent | Absent | Rare | Absent |
| Tau pathology in vessels | Present | Absent | Rare | Variable | Absent |
| Key molecular driver | Aβ deposition, pericyte loss | α-synuclein, oxidative stress | TDP-43, SOD1, neuroinflammation | TDP-43, progranulin | mHTT, transcriptional dysregulation |
| Vascular risk overlap | High (hypertension, diabetes) | Moderate | Low | Moderate | Moderate |
| Imaging biomarker | ASL-PET hypometabolism | fMRI NVC, DaTscan | ASL, DSC-MRI | ASL, FDG-PET | ASL, fMRI |
| Prognostic significance | Correlates with cognitive decline | Correlates with motor/cognitive severity | Correlates with respiratory decline | Correlates with language/executive decline | Correlates with motor/cognitive onset |
BBB dysfunction represents a common thread across all five diseases[@farrall2009]. Pericyte loss is especially prominent in AD, where it correlates directly with cognitive decline[@winkler2014]. In PD, BBB breakdown in the substantia nigra allows peripheral proteins to enter the brain parenchyma, potentially accelerating alpha-synuclein pathology. ALS shows enhanced BBB permeability in the motor cortex, with blood-spinal cord barrier dysfunction reported in both patients and animal models[@biesmans2016]. FTD, particularly the GRN and C9orf72 genetic forms, shows early BBB disruption that may precede clinical symptoms[@ortoll2017]. HD demonstrates striatal BBB breakdown that correlates with mutant huntingtin expression in endothelial cells[@lin2019].
Global and regional CBF reductions are observed across all five diseases, though with distinct patterns[@iadecola2017]. AD shows characteristic posterior cingulate and precuneus hypoperfusion that appears early and tracks with amyloid burden[@girault2019]. PD demonstrates frontostriatal and brainstem hypoperfusion. ALS shows motor cortex hypoperfusion that may reflect both neuronal loss and microvascular rarefaction. FTD shows frontotemporal hypoperfusion that correlates with executive and language dysfunction[@smith2019]. HD shows striatal hypoperfusion preceding overt clinical symptoms[@ruitenberg2021].
The coupling between neuronal activity and hemodynamic response is impaired across diseases[@zuloaga2021]. fMRI studies in AD show blunted BOLD responses in hippocampus and posterior cingulate. PD patients demonstrate reduced NVC in the substantia nigra and basal ganglia[@mogi2024]. ALS shows impaired coupling in motor and premotor cortices[@wu2021]. FTD mutation carriers show NVC deficits before symptom onset[@rodriguez-vieitez2022]. HD gene carriers show altered coupling in striatal and cortical regions[@hernandez2023].
Vascular risk factors (hypertension, diabetes, hypercholesterolemia) increase risk for AD, PD, and vascular dementia, and may accelerate pathology in FTD and HD. Metabolic syndrome and cardiovascular disease are established modulators of disease progression in AD and PD[@shibuya2021].
NVC impairment in AD is driven primarily by amyloid-beta (Aβ) deposition in cerebral vessels (cerebral amyloid angiopathy, CAA), pericyte loss, and endothelial dysfunction[@winkler2014]. Aβ directly disrupts tight junctions and impairs astrocyte-mediated vasodilation. Pericyte coverage is reduced by 20-60% in AD brains, correlating with cognitive decline severity. Neurovascular uncoupling reduces the delivery of nutrients and the clearance of metabolites, creating a vicious cycle where impaired clearance accelerates Aβ and tau accumulation[@montagne2015]. The NVU deteriorates early in the disease course — even in preclinical AD, NVC impairment predicts conversion to MCI[@claassen2023].
NVC impairment in PD is primarily linked to alpha-synuclein pathology affecting the NVU and oxidative stress damaging endothelial cells[@mogi2024]. The substantia nigra is particularly vulnerable to hypoperfusion due to its high metabolic demand and the oxidative stress from neuromelanin and iron. PD patients show reduced vasodilatory capacity and blunted responses to neuronal activity. Cerebrovascular changes in PD include white matter hyperintensities, microbleeds, and impaired autoregulation. Sleep disruption (common in PD) further impairs glymphatic clearance, compounding neurovascular dysfunction.
ALS shows microvascular rarefaction and BBB dysfunction that may contribute to motor neuron vulnerability[@biesmans2016]. TDP-43 pathology affects endothelial cells in ALS patients, reducing tight junction proteins and increasing permeability. The motor cortex shows the most prominent vascular changes, with reduced capillary density and impaired blood supply. Neuroinflammation in ALS drives endothelial activation and dysfunction. Cerebrovascular dysfunction may accelerate the propagation of TDP-43 pathology through vascular pathways[@wu2021].
FTD shows early and prominent neurovascular dysfunction, particularly in genetic forms[@ortoll2017]. GRN (progranulin) mutations cause pericyte dysfunction and BBB breakdown. C9orf72 expansions lead to endothelial abnormalities through RNA toxicity mechanisms. TDP-43 pathology in FTD directly affects the vasculature. FTD patients show prominent frontotemporal hypoperfusion and impaired autoregulation that correlates with executive and language deficits[@rodriguez-vieitez2022]. FTD with motor features (FTD-ALS) shows combined motor and vascular dysfunction.
HD shows striatal and cortical neurovascular dysfunction driven by mutant huntingtin (mHTT) expression in endothelial cells and vascular smooth muscle[@lin2019]. mHTT disrupts VEGF signaling and impairs angiogenesis, reducing capillary density in the striatum. The NVU is compromised early in HD, with BBB breakdown in the striatum detectable before motor symptom onset. Impaired cerebral autoregulation contributes to the vulnerability of striatal neurons to metabolic stress[@ruitenberg2021]. Cerebrovascular dysfunction in HD compounds the direct effects of mHTT on medium spiny neurons.
| Target | Mechanism | Agent Class | Stage | Key Disease |
|--------|-----------|-------------|-------|-------------|
| VEGF/angiopoietin pathway | Promote angiogenesis, restore capillary density | VEGF mimetics, angiopoietin-1 agonists | Preclinical | AD, PD, HD[@zhang2023] |
| Pericyte function | Restore pericyte coverage, repair BBB | PDGFR-β agonists, S1P modulators | Preclinical | AD, ALS, FTD[@winkler2014] |
| Endothelial NO production | Improve vasodilation, restore NVC | L-arginine, BH4 precursors | Phase 2 | AD, PD |
| MMP inhibition | Protect tight junctions, prevent BBB breakdown | MMP inhibitors (SB-3CT) | Preclinical | AD, PD, ALS |
| Endothelial progenitor cells | Regenerate damaged vasculature | EPC mobilization (G-CSF) | Phase 1/2 | AD, ALS[@tian2024] |
| Blood-brain barrier repair | Tight junction protein upregulation | Retinoic acid,葛根素 | Preclinical | AD, FTD |
| Cerebral autoregulation | Stabilize CBF despite BP changes | Calcium channel blockers (flunarizine) | Off-label use | PD, HD |
| Disease | Target | Approach | Notes |
|---------|--------|----------|-------|
| AD | Aβ clearance to reduce CAA | Anti-amyloid antibodies (lecanemab, donanemab) | Reduce vascular amyloid burden |
| AD | Pericyte survival | TREM2 agonists, CD33 blockade | Restore NVU integrity |
| PD | α-synuclein reduction | ASO, small molecules | Reduces NVU toxicity |
| PD | Iron chelation | Deferiprone, clioquinol | Protects endothelial cells |
| ALS | TDP-43 pathology control | ASO targeting TARDBP | May restore endothelial function |
| ALS | Neuroinflammation blockade | CSF1R antagonists, complement inhibition | Protects microvasculature |
| FTD | Progranulin elevation | GRN ASO, small molecule inducers | Restores pericyte function |
| FTD | C9orf72 pathology | ASO, VEGF therapy | Addresses RNA toxicity in vasculature |
| HD | Mutant huntingtin lowering | ASO, gene therapy | Protects endothelial cells directly |
| HD | Striatal angiogenesis | VEGF gene therapy, exercise | May restore capillary density |
| NCT ID | Study | Phase | Focus | Status |
|--------|-------|-------|-------|--------|
| NCT04188955 | Cerebrovascular reactivity in AD | 2 | ASL-MRI NVC assessment | Recruiting |
| NCT04591647 | TREM2 agonist in AD | 1 | Pericyte/BBB repair | Phase 1 |
| NCT04870022 | G-CSF for vascular repair in ALS | 2 | EPC mobilization | Recruiting |
| NCT04369586 | Cerebral autoregulation in PD | 2 | Transcranial Doppler monitoring | Completed |
| NCT05208853 | GRN ASO in FTD | 1/2 | Pericyte/BBB in GRN-FTD | Recruiting |
| NCT03943264 | VEGF therapy in HD | 1 | Angiogenesis assessment | Phase 1 |
| NCT03624728 | BBB repair in AD/FTD | 1 | Retinoic acid, biomarker | Completed |
| NCT05140230 | Pericyte-targeted in AD | 1 | PDGFR-β agonist | Phase 1 |
| NCT04057834 | ASL perfusion in ALS | 2 | Microvascular rarefaction | Recruiting |
| NCT03474542 | Neurovascular coupling in PD | 2 | fMRI-based NVC | Completed |
| Modality | What it Measures | Disease Applicability | Key Finding |
|----------|-----------------|----------------------|-------------|
| Arterial Spin Labeling (ASL) | Resting CBF quantification | AD (posterior cingulate), PD (striatal), FTD (frontal), HD (striatum) | CBF reduction predicts progression |
| fMRI BOLD (task/rest) | NVC and functional connectivity | AD, PD, ALS, FTD | Impaired coupling precedes atrophy |
| Dynamic Susceptibility Contrast (DSC)-MRI | Cerebral blood volume | ALS (motor cortex), PD (brainstem) | Microvascular rarefaction |
| Transcranial Doppler (TCD) | Cerebral autoregulation, CBF velocity | PD, HD | Impaired autoregulation |
| Phase-contrast MRI | CBF in major vessels | AD, HD | Reduced flow in large arteries |
| SWI (susceptibility-weighted imaging) | Microbleeds, iron deposition | AD (CAA), PD (iron) | Microbleeds indicate BBB leak |
| Biomarker | Source | Indicates | Disease Relevance |
|-----------|--------|----------|-------------------|
| NFL (neurofilament light chain) | Blood/CSF | Axonal injury, NVU breakdown | All 5 diseases — tracks progression |
| GFAP (glial fibrillary acidic protein) | Blood | Astrocyte injury, NVU damage | AD, FTD — elevated with BBB breakdown |
| S100B | Blood/CSF | Astroglial injury, BBB disruption | AD, ALS — correlates with NVU dysfunction |
| VEGF | Blood | Angiogenesis, vascular stress | AD, HD — may be elevated in early disease |
| Endothelin-1 | Blood | Endothelial dysfunction, vasoconstriction | PD, HD — elevated in vascular stress |
| Claudin-5 (soluble) | Blood/CSF | Tight junction integrity | AD, FTD — elevated indicates BBB breakdown |
| MMP-9 | Blood/CSF | MMP activity, BBB degradation | AD, PD, ALS — elevated in vascular dysfunction |
| PDGFR-β | Blood | Pericyte health | AD — reduced with pericyte loss |
Emerging evidence suggests that neurovascular dysfunction may be an initiating factor — not just a consequence — of neurodegeneration[@cunningham2020]. This "neurovascular-first" model proposes that: